TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TELA Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.97−0.00 (-0.48%)
Close on Oct 19, 2026
- Market cap
- $55.71M
- P/E (TTM)
- –
- Dividend yield
- –
TELA Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | TELA Bio | Industry median |
|---|---|---|
| Market Cap | $43.56M | $230.55M |
| Enterprise Value | $69.22M | $202.97M |
| PS Ratio | 0.55 | 3.10 |
Enterprise value
| Measure | TELA Bio | Industry median |
|---|---|---|
| EV / Sales | 0.87 | 2.91 |
Income (trailing twelve months)
| Measure | TELA Bio | Industry median |
|---|---|---|
| Revenue | $79.91M | $102.39M |
| Gross Profit | $54.19M | $60.36M |
| Operating Income | -$34.01M | -$4.31M |
| Pretax Income | -$40.91M | -$2.37M |
| Net Income | -$41.18M | -$6.57M |
| EBITDA | -$34.01M | -$1.98M |
| EPS (Diluted) | -$0.77 | -$0.08 |
Margins
| Measure | TELA Bio | Industry median |
|---|---|---|
| Gross Margin | 67.8% | 55.2% |
| Operating Margin | -42.6% | -6.04% |
| Pretax Margin | -51.2% | -4.11% |
| Profit Margin | -51.5% | -10.5% |
| EBITDA Margin | -42.6% | -2.67% |
| FCF Margin | -39.6% | 0.02% |
Returns
| Measure | TELA Bio | Industry median |
|---|---|---|
| Return on Assets (ROA) | -64.7% | -13.3% |
| Return on Invested Capital (ROIC) | -211.7% | -3.69% |
| Return on Capital Employed (ROCE) | -81.9% | -9.07% |
Growth
| Measure | TELA Bio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.09% | 8.85% |
| Revenue Growth (3Y CAGR) | 24.7% | 7.08% |
| Revenue Growth (5Y CAGR) | 34.5% | 11.8% |
Balance sheet
| Measure | TELA Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $30.42M | $36.66M |
| Total Debt | $56.08M | $97.65M |
| Net Cash (Debt) | -$25.66M | $3.92M |
| Net Cash Per Share | -$0.57 | $0.28 |
| Equity (Book Value) | -$15.87M | $55.33M |
| Book Value Per Share | -$0.35 | $2.87 |
| Tangible Book Value | -$17.04M | $10.79M |
| Working Capital | $36.27M | $56.72M |
Financial position
| Measure | TELA Bio | Industry median |
|---|---|---|
| Current Ratio | 2.99 | 2.48 |
| Quick Ratio | 2.20 | 1.53 |
| Interest Coverage | -4.88 | -1.85 |
Cash flow (trailing twelve months)
| Measure | TELA Bio | Industry median |
|---|---|---|
| Operating Cash Flow | -$31.14M | -$566.22K |
| Capital Expenditures | -$480.00K | -$3.69M |
| Free Cash Flow | -$31.62M | -$696.00K |
| FCF Per Share | -$0.70 | -$0.02 |
Efficiency
| Measure | TELA Bio | Industry median |
|---|---|---|
| Asset Turnover | 1.26 | 0.58 |
| Inventory Turnover | 2.26 | 2.21 |
| Revenue Per Employee | $366.55K | $322.92K |
| Profits Per Employee | -$188.89K | -$51.88K |
| Employee Count | 218 | 185 |
Dividends and yields
| Measure | TELA Bio | Industry median |
|---|---|---|
| Earnings Yield | -94.5% | -6.88% |
| FCF Yield | -72.6% | -0.45% |
Shares
| Measure | TELA Bio | Industry median |
|---|---|---|
| Shares Outstanding | 44,894,800 | 44,302,700 |
| Shares Change (YoY) | 36.2% | 3.36% |
| Shares Change (QoQ) | 0.15% | 0.27% |
| Float | 25,320,000 | 37,462,700 |
| Shares Held by Insiders | 43.6% | 10.5% |
| Shares Held by Institutions | 70.5% | 63.5% |
Taxes
| Measure | TELA Bio | Industry median |
|---|---|---|
| Income Tax | $265.00K | $1.52M |
Scores
| Measure | TELA Bio | Industry median |
|---|---|---|
| Altman Z-Score | -9.34 | 1.95 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from TELA Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.